Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.
MRNA is in a consolidation phase with a slight bullish bias in the very short term, but it remains within a larger corrective structure.
Valuation is challenging due to negative earnings. The stock trades at a premium to book value (P/B 2.46) and an elevated P/S multiple (8.85), reflecting market expectations for future pipeline sales rather than current earnings. Based purely on current financials, the stock appears overvalued, but its price could be justified as a fair entry point for a high-risk investment if one assigns high probability to pipeline success.
